Is There an Optimum Overall Time for Head and Neck Radiotherapy? A Review, with New Modelling

Clinical Oncology

Volumn 19, Issue 1, 2007, Pages 8-22

  Fowler, J F ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Constraints; fractionation; head and neck; linear quadratic; modelling; mucosal; oropharyngeal; schedules

Indexed keywords

APOPTOSIS; ARTICLE; CALCULATION; CANCER MODEL; CANCER RADIOTHERAPY; CLINICAL TRIAL; DOSE RESPONSE; DOSIMETRY; FEASIBILITY STUDY; FRACTIONATION; HEAD AND NECK CANCER; HUMAN; META ANALYSIS; ORAL MUCOSAL DISEASE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION SAFETY; SYSTEMATIC REVIEW; TUMOR CELL;

DOSE FRACTIONATION; GREAT BRITAIN; HEAD AND NECK NEOPLASMS; HUMANS; LINEAR MODELS; RADIOTHERAPY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TIME FACTORS;

EID: 33845994029     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2006.09.008     Document Type: Article

References (42)

1. Bentzen S.M. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 6 (2005) 112-117
2. Horiot J.C., Le Fur R., N'guyen T., et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma; final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 25 (1992) 231-241
3. Horiot J.C., Bontemps P., Van den Bogaert W., et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 44 (1997) 111-121
4. Fu K.K., Pajak T.F., Trotti A., et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas; first report of RTOG 90-03. Int J Radiat Oncol Biol Phys 48 (2000) 7-16
5. Overgaard J., Hansen H.S., Specht L., et al. Five compared with six fractions per week of conventional radiotherapy of squamous cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial. Lancet 362 (2003) 933-940
6. Bourhis J., Etessami A., Pignon J.P., et al. Altered fractionated radiotherapy in the management of head and neck carcinomas: advantages and limitations. Curr Opin Oncol 16 (2004) 215-219
7. Skladowski K., Maciejewski B., Golen, et al. Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer - report on 3 year tumour control and normal tissue toxicity. Radiother Oncol 55 (2000) 101-110
8. Fowler J.F. Review article: the linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62 (1989) 679-694
9. Fowler J.F. Practical time-dose evaluation, or how to stop worrying and learn to love linear quadratics. In: Levitt S.H., Purdy J.A., Perez C.A., and Vijayakumar S. (Eds). Technical basis of radiation therapy (2006), Springer, Berlin 3-31 4th rev. edn
10. Niemierko A. Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys 24 (1997) 103-110
11. Fowler J.F., Harari P.M., Leborgne F., and Leborgne J.H. Acute radiation reactions in oral and pharyngeal mucosa: tolerable levels in altered fractionation schedules. Radiother Oncol 69 (2003) 161-168
12. Barendsen G.W. Dose fractionation, dose rate, and isoeffect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 8 (1982) 1981-1997
13. Kaanders J.H.A.M., van der Kogel A.J., and Ang K.K. Altered fractionation: limited by mucosal reactions?. Radiother Oncol 22 (1999) 81-91
14. Kaanders J.H., Pop L.A., Marres H.A., et al. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 52 (2002) 769-778
15. Bentzen S.M., Ruifrok A.C.C., and Thames H.D. Repair capacity and kinetics for human mucosa and epithelial tumours in the head and neck: clinical data on the effect of changing the time interval between multiple fractions per day in radiotherapy. Radiother Oncol 38 (1996) 89-101
16. Bentzen S.M., Saunders M.I., and Dische S. Repair half-times estimated from observations of treatment related morbidity after CHART or conventional radiotherapy in head and neck cancer. Radiother Oncol 53 (1999) 219-226
17. Fowler J.F. Repair between dose fractions: a simpler method of analyzing and reporting apparently biexponential repair. Radiat Res 158 (2002) 141-151
18. Fowler J.F., Welsh J.S., and Howard S.P. Loss of biological effect in prolonged fraction delivery. Int J Radiat Oncol Biol Phys 59 (2004) 242-249
19. Fowler J.F., Bentzen S.M., Bond S.J., et al. Clinical radiation doses for spinal cord: the 1998 international questionnaire. Radiother Oncol 55 (2000) 295-300
20. Fowler J.F. The radiobiology of prostate cancer: new aspects of fractionated radiotherapy. Acta Oncol 44 (2005) 265
21. Leborgne F., and Fowler J.F. Acute toxicity following hypofractionated conformal radiotherapy of localized prostate cancer. A nonrandomized contemporary comparison with standard fractionation. In: Mehta M., Paliwal B.R., and Bentzen S.M. (Eds). Physical, chemical and biological targeting in radiation oncology. 7th International Conference on Time, Dose and Fractionation in Radiation Oncology. AAPM Symposium Proceedings, no. 14 (2005) 131-132
22. Huang E.H., Pollack A., Levy L., et al. Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 54 (2002) 1314-1321
23. Vargas C., Kestin L.L., Martinez A.A., et al. Dose-volume analysis of predictors for chronic rectal toxicity following treatment of prostate cancer with high-dose conformal radiotherapy. ASTRO abstract 2093. Int J Radiat Oncol Biol Phys 57 2S (2003) S398-S399
24. Denham J.W., and Kron T. Extinction of the weakest. Int J Radiat Oncol Biol Phys 51 (2001) 807-819
25. Dörr W., Hamilton C.S., Boyd T., et al. Radiation induced changes in cellularity and proliferation in human oral mucosa. Int J Radiat Oncol Biol Phys 52 (2002) 911-917
26. Roberts S.A., and Hendry J.H. Time factors in larynx radiotherapy: lag times and intertumor heterogeneity in clinical datasets from four centers. Int J Radiat Oncol Biol Phys 45 (1999) 1247-1257
27. Brenner B.J. Accelerated repopulation during radiotherapy. Quantitative evidence for delayed onset. Radiat Oncol Invest 1 (1993) 167-172
28. Bentzen S.M., Saunders M.I., and Dische S. From CHART to CHARTWEL in non-small-cell lung cancer: clinical radiobiological modelling of the expected change in outcome. Clin Oncol (R Coll Radiol) 14 (2002) 372-381
29. Withers H.R., Taylor J.M.G., and Maciejewski B. The hazard of accelerated clonogen repopulation during radiotherapy. Acta Oncol 27 (1988) 131-146
30. Fowler J.F., and Lindstrom M.J. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 23 (1992) 457-467
31. McGinn C.J., Harari P.M., Fowler J.F., et al. Intensification in curative head and neck cancer radiation therapy: linear quadratic analysis and preliminary assessment of clinical results. Int J Radiat Oncol Biol Phys 27 (1993) 363-369
32. Wang C.C. Local control of oropharyngeal carcinoma after two accelerated hyperfractionation radiation therapy schemes. Int J Radiat Oncol Biol Phys 14 (1988) 1143-1146
33. Leborgne F., Leborgne J.H., Fowler J.F., Zubizarreta E., and Mezzerfa J. Accelerated hyperfractionated irradiation for advanced head and neck cancer: effect of shortening the median treatment duration by 13 days. Head & Neck 23 (2001) 661-668
34. Slevin N.J., Hendry J.H., Roberts S.A., et al. The effect of increasing the treatment time beyond three weeks on the control of T2 and T3 laryngeal cancer using radiotherapy. Radiother Oncol 42 (1992) 215-220
35. Zackrisson B., Franzen L., Henriksson R., and Littbrand B. Tolerance to accelerated fractionation in the head and neck region. Acta Oncol 33 (1994) 391-396
36. Sanguinetti G., Sosa M., Endres E., et al. Hyperfractionated IMRT (HF-IMRT) alone for locally advanced oropharyngeal carcinoma: a phase I study. Radiother Oncol 73 Suppl 1 (2004) S300
37. Poulsen M., Denham J., Peters L., et al. A randomized trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinomas of the head and neck: a Trans-Tasman Radiation Oncology Group study (TROG 91.01). Radiother Oncol 60 (2001) 113-122
38. Dische S., Saunders M.I., Barrett A., et al. A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 44 (1997) 123-126
39. Budach V., Stuschke M., Budach W., et al. Hyperfractionated accelerated chemoradiation with concurrent FU-mitomycin - final results of the Radiotherapy German Cancer Society 95-06 prospective randomized trial. J Clin Oncol 23 (2005) 1125-1135
40. Bentzen S.M. Towards evidence based radiation oncology: improving the design, analysis, and reporting of clinical outcome studies in radiotherapy. Radiother Oncol 46 (1998) 5-18
41. Smid E.J., Stoter T.R., Bloemena E., et al. The importance of immunohistochemical expression of EGFr in squamous cell carcinoma of the oral cavity treated with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 65 (2006) 1323-1329
42. Bourhis J, Overgaard J, Aurdy H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. www.thelancet.com. Published online August 17, 2006.